# High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib

> **NCT06394674** · PHASE2 · RECRUITING · sponsor: **Changhai Hospital** · enrollment: 84 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Furmonertinib

## Key facts

- **NCT ID:** NCT06394674
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-01
- **Primary completion:** 2025-06
- **Final completion:** 2026-09
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-07-26

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06394674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06394674, "High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06394674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*